Skip to content

Treatment and safety

What did the TRAVERSE trial find about testosterone and heart risk?

In TRAVERSE, men with low testosterone and higher cardiovascular risk who received testosterone did not have more major heart events than those on placebo over the study period. Some other risks were higher.

The trial reported higher rates of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group.

The FDA updated testosterone labeling in 2025 to reflect these findings, and your clinician weighs them with your own history.

Risks and limitations

  • One trial does not answer every question, and individual cardiovascular history still matters.

Sources

Start with a conversation

Request a call and an MMI team member will reach out to talk through next steps. A request is not a booked appointment.

Request a Call